Crinetics Pharmaceuticals, Inc.

Crinetics' 15.74% short interest stands out as notably elevated for a biotech name, suggesting meaningful skepticism despite the stock trading 18% below its 52-week high. The company's lack of earnings (n/a P/E) indicates it remains pre-profitability or unprofitable, typical for pharmaceutical development-stage firms, yet the $4.0B market cap reflects substantial investor conviction in its pipeline. With RSI at 42.6, the stock sits in neutral territory—neither oversold nor overbought—offering no immediate technical extremes. The combination of high short interest, development-stage status, and mid-range technicals creates potential squeeze dynamics if clinical or regulatory catalysts materialize, though the elevated short positioning also reflects real execution risk ahead.